Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal
Ben Kearns,Myfanwy Lloyd Jones,Matt Stevenson,Chris LittlewoodVolume:
31
Language:
english
Journal:
PharmacoEconomics
DOI:
10.1007/s40273-013-0050-9
Date:
June, 2013
File:
PDF, 346 KB
english, 2013